Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-29, Stock:NVS, The news for the past five days is as follows:
2018-08-22: NEWS1: Incyte’s Revenue Stream in Q2 2018.NEWS2: Insight: Toxin at heart of drug recall shows holes in medical safety net.NEWS3: Toxin at heart of drug recall shows holes in medical safety net.NEWS4: The Swiss Stock Market Pulled Back In Cautious Trade.NEWS5: The Swiss Stock Market Pulled Back In Cautious Trade.
2018-08-23: NEWS1: Novartis Breast Cancer Drug Meets Primary Goal in Phase III.NEWS2: Novartis Breast Cancer Drug Meets Primary Goal in Phase III.NEWS3: Update on Roche’s Oncology Drugs: Tarceva, Cotellic, and Erivedge.NEWS4: Roche: Recent Developments and Analysts’ Ratings in August.NEWS5: Novartis Breast Cancer Drug Meets Primary Goal in Phase III.NEWS6: CYRX: Commercial Support and Clinical Trial Revenue Ramping. Commercial Support Pipeline Increasing Long-Term Value.NEWS7: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS8: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS9: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero.NEWS10: The Swiss Stock Market Held Onto A Small Gain.NEWS11: The Swiss Stock Market Held Onto A Small Gain.NEWS12: European Markets Finished Mostly Lower In Choppy Trade.NEWS13: European Markets Finished Mostly Lower In Choppy Trade.NEWS14: Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio.NEWS15: How Incyte’s Product Portfolio Is Looking in August.NEWS16: Novartis Breast Cancer Drug Trial a Success.NEWS17: Novartis: Phase III SOLAR-1 Trial On PI3K Inhibitor BYL719 Met Primary Goal.NEWS18: Novartis: Phase III SOLAR-1 Trial On PI3K Inhibitor BYL719 Met Primary Goal.
2018-08-24: NEWS1: Merck, Eisai Get EU Approval for Lenvima Label Expansion.NEWS2: Merck, Eisai Get EU Approval for Lenvima Label Expansion.NEWS3: Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test.NEWS4: Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test.NEWS5: AstraZeneca's Bevespi Unimpressive in Phase III COPD Study.NEWS6: AstraZeneca's Bevespi Unimpressive in Phase III COPD Study.NEWS7: An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept.NEWS8: Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test.NEWS9: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for August 27, 2018.NEWS10: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for August 27, 2018.NEWS11: Roche’s Immunology Drug Actemra: A Long-Term Growth Driver?.NEWS12: Novartis’s SOLAR-1 Trial Met Primary Endpoint.NEWS13: The Swiss Stock Market Clung To A Small Gain After Late Pullback.NEWS14: The Swiss Stock Market Clung To A Small Gain After Late Pullback.NEWS15: An Update on Roche’s Immunology Drugs: Xolair and Esbriet.NEWS16: [$$] Digital therapeutics show potential for healthcare disruption.
2018-08-27: NEWS1: Novartis' CAR-T Therapy Kymriah Gets Approval in Europe.NEWS2: Novartis' CAR-T Therapy Kymriah Gets Approval in Europe.NEWS3: Novartis wins EU approval for blood cancer therapy Kymriah.NEWS4: 5 Reasons Why You Should Add Lilly Stock to Your Portfolio.NEWS5: 5 Reasons Why You Should Add Lilly Stock to Your Portfolio.NEWS6: Ocrevus Could Boost Roche’s Revenue Growth in 2018 and Beyond.NEWS7: The Swiss Stock Market Climbed At The Start Of The Week.NEWS8: The Swiss Stock Market Climbed At The Start Of The Week.NEWS9: [$$] Novartis to boost ability to manufacture new cancer drug in Europe.NEWS10: Novartis's Kymriah wins EU approval for blood cancer treatment.NEWS11: Novartis Reports European Commission Approval Of Kymriah CAR-T Cell Therapy.NEWS12: Novartis Reports European Commission Approval Of Kymriah CAR-T Cell Therapy.
2018-08-28: NEWS1: Novartis’s Business Segments in Q2 2018.NEWS2: Why Ionis Pharmaceuticals Stock Is Plummeting Today.NEWS3: Gilead's CAR-T Therapy Yescarta Gets Approval in Europe.NEWS4: Gilead's CAR-T Therapy Yescarta Gets Approval in Europe.NEWS5: Novartis’s Quarterly Revenue Trend in Q2 2018.NEWS6: Novartis’s Valuation in August.NEWS7: The Swiss Stock Market Pulled Back As Defensive Heavyweights Fell.NEWS8: The Swiss Stock Market Pulled Back As Defensive Heavyweights Fell.NEWS9: Lucentis and Hemlibra Could Boost Roche’s Revenue Growth.

Answer: Decrease